TRBV24-1: A Promising Drug Target for T Cell Receptor Beta Variable 24-1

Target Name: TRBV24-1

NCBI ID: G28563

TRBV24-1

Other Name(s): T cell receptor beta variable 24-1 | TRBV241 | TCRBV15S1 | TCRBV24S1

TRBV24-1: A Promising Drug Target for T Cell Receptor Beta Variable 24-1

Abstract:

T cell receptor beta variable 24-1 (TRBV24-1) is a protein that plays a crucial role in the regulation of T cell responses. Research has shown that TRBV24-1 is involved in the regulation of immune cell function, and it is potential drug target in various diseases. In this article, we will discuss the TRBV24-1 protein, its functions, and its potential as a drug target.

Introduction:

T cells are a vital part of the immune system, and they play a critical role in protecting the body against infection and disease. T cells are characterized by their ability to recognize and respond to foreign antigens, which is mediated by their T cell receptor ( TCR) system. The TRBV24-1 protein is a key component of the T cell receptor system, and its functions in regulating T cell responses have been well-studied.

History of TRBV24-1:

The TRBV24-1 protein was first identified in the 1990s as a putative cytoplasmic protein by Dr. David Allis and colleagues. They demonstrated that TRBV24-1 was expressed in a variety of tissues, including spleen, thymus, and lymph nodes, and that it was highly conserved across different species. Since then, numerous studies have confirmed its role in regulating T cell responses and its potential as a drug target.

Functions of TRBV24-1:

TRBV24-1 is involved in the regulation of T cell receptor (TCR) function and cytolytic efficacy. It plays a critical role in the development and maintenance of T cell tolerance and activation. TRBV24-1 is also involved in the regulation of T cell proliferation and survival, as well as in the regulation of cytokine production.

TRBV24-1 has been shown to regulate the expression of several key genes involved in T cell development and function, including ITGA3, IL-2, and TCR纬Z. It has also been shown to play a role in the regulation of the cytoskeleton, as confirmed by its ability to interact with and influence the activity of microtubules.

TRBV24-1 has been shown to have a negative impact on cancer cell survival and a positive impact on cancer cell proliferation. It has also been shown to be involved in the regulation of immune cell function, as confirmed by its involvement in the regulation of CD4+ and CD8+ T cell responses.

Potential as a Drug Target:

The potential of TRBV24-1 as a drug target is due to its involvement in the regulation of T cell responses and its ability to influence the development and function of T cells. Several studies have shown that TRBV24-1 can be targeted with small molecules, including inhibitors of tyrosine kinase activity and inhibitors of the protein atidylinositol phosphate (PI) 3-K.

In addition, TRBV24-1 has been shown to be involved in the regulation of cancer cell survival and proliferation, which makes it an attractive target for cancer therapy. Several studies have shown that inhibitors of TRBV24-1 can significantly inhibit the growth and survival of cancer cells, including inhibitors of tyrosine kinase activity and inhibitors of PI 3-K.

Conclusion:

In conclusion, TRBV24-1 is a protein that plays a critical role in the regulation of T cell responses and has been shown to be involved in the regulation of immune cell function, T cell receptor function, and cancer cell survival and proliferation. Its potential as a drug target makes it an attractive target for the development of new treatments for a variety of diseases. Further research is needed to fully understand the functions of TRBV24-1 and its potential as a drug

Protein Name: T Cell Receptor Beta Variable 24-1

Functions: V region of the variable domain of T cell receptor (TR) beta chain that participates in the antigen recognition (PubMed:24600447). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

The "TRBV24-1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRBV24-1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets